Corticosteroid-associated osteonecrosis in children

Scott Rosenfeld, Harry K W Kim

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Corticosteroids are potent anti-inflammatory drugs used to treat various adult and pediatric medical conditions. More than 30 million Americans receive corticosteroids as part of their treatment protocols for acute and chronic illnesses [1, 2]. Use of systemic corticosteroids in children has been most thoroughly studied in patients treated for acute lymphocytic leukemia (ALL), systemic lupus erythematosus (SLE), and renal transplant. In the case of ALL, the addition of corticosteroids to antileukemic protocols has been shown to improve the remission rate [3]. Current treatment protocols characterized by chemotherapy intensified by higher-dose corticosteroids are thought to be partly responsible for improved outcomes in ALL with cure rates ranging from 70 to 90 % [3–7]. In pediatric SLE, long-term survival has improved dramatically as corticosteroids have become the mainstay of treatment [8]. Depending on the specific disease and severity, the length of treatment ranges from days to years to a lifetime of use. As with many medications, chronic use may result in adverse side effects. Such effects of corticosteroids have been described in multiple organ systems including the musculoskeletal system [9]. The specific effect of hypercortisolism on bone was first recognized as a feature of Cushing’s disease. Since that time, the cause-effect relationship between corticosteroid treatment and bone disease such as osteoporosis, fractures, and osteonecrosis has become more clearly established [10–12].

Original languageEnglish (US)
Title of host publicationOsteonecrosis
PublisherSpringer Berlin Heidelberg
Pages479-490
Number of pages12
ISBN (Print)9783642357671, 9783642357664
DOIs
StatePublished - Jan 1 2014

Fingerprint

Osteonecrosis
Adrenal Cortex Hormones
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical Protocols
Systemic Lupus Erythematosus
Pediatrics
Pituitary ACTH Hypersecretion
Musculoskeletal System
Cushing Syndrome
Bone Diseases
Osteoporosis
Chronic Disease
Anti-Inflammatory Agents
Therapeutics
Transplants
Kidney
Bone and Bones
Drug Therapy
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rosenfeld, S., & Kim, H. K. W. (2014). Corticosteroid-associated osteonecrosis in children. In Osteonecrosis (pp. 479-490). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-35767-1_63

Corticosteroid-associated osteonecrosis in children. / Rosenfeld, Scott; Kim, Harry K W.

Osteonecrosis. Springer Berlin Heidelberg, 2014. p. 479-490.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rosenfeld, S & Kim, HKW 2014, Corticosteroid-associated osteonecrosis in children. in Osteonecrosis. Springer Berlin Heidelberg, pp. 479-490. https://doi.org/10.1007/978-3-642-35767-1_63
Rosenfeld S, Kim HKW. Corticosteroid-associated osteonecrosis in children. In Osteonecrosis. Springer Berlin Heidelberg. 2014. p. 479-490 https://doi.org/10.1007/978-3-642-35767-1_63
Rosenfeld, Scott ; Kim, Harry K W. / Corticosteroid-associated osteonecrosis in children. Osteonecrosis. Springer Berlin Heidelberg, 2014. pp. 479-490
@inbook{7d3c6f775ad54046b6c6d0322a3ab90a,
title = "Corticosteroid-associated osteonecrosis in children",
abstract = "Corticosteroids are potent anti-inflammatory drugs used to treat various adult and pediatric medical conditions. More than 30 million Americans receive corticosteroids as part of their treatment protocols for acute and chronic illnesses [1, 2]. Use of systemic corticosteroids in children has been most thoroughly studied in patients treated for acute lymphocytic leukemia (ALL), systemic lupus erythematosus (SLE), and renal transplant. In the case of ALL, the addition of corticosteroids to antileukemic protocols has been shown to improve the remission rate [3]. Current treatment protocols characterized by chemotherapy intensified by higher-dose corticosteroids are thought to be partly responsible for improved outcomes in ALL with cure rates ranging from 70 to 90 {\%} [3–7]. In pediatric SLE, long-term survival has improved dramatically as corticosteroids have become the mainstay of treatment [8]. Depending on the specific disease and severity, the length of treatment ranges from days to years to a lifetime of use. As with many medications, chronic use may result in adverse side effects. Such effects of corticosteroids have been described in multiple organ systems including the musculoskeletal system [9]. The specific effect of hypercortisolism on bone was first recognized as a feature of Cushing’s disease. Since that time, the cause-effect relationship between corticosteroid treatment and bone disease such as osteoporosis, fractures, and osteonecrosis has become more clearly established [10–12].",
author = "Scott Rosenfeld and Kim, {Harry K W}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-35767-1_63",
language = "English (US)",
isbn = "9783642357671",
pages = "479--490",
booktitle = "Osteonecrosis",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Corticosteroid-associated osteonecrosis in children

AU - Rosenfeld, Scott

AU - Kim, Harry K W

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Corticosteroids are potent anti-inflammatory drugs used to treat various adult and pediatric medical conditions. More than 30 million Americans receive corticosteroids as part of their treatment protocols for acute and chronic illnesses [1, 2]. Use of systemic corticosteroids in children has been most thoroughly studied in patients treated for acute lymphocytic leukemia (ALL), systemic lupus erythematosus (SLE), and renal transplant. In the case of ALL, the addition of corticosteroids to antileukemic protocols has been shown to improve the remission rate [3]. Current treatment protocols characterized by chemotherapy intensified by higher-dose corticosteroids are thought to be partly responsible for improved outcomes in ALL with cure rates ranging from 70 to 90 % [3–7]. In pediatric SLE, long-term survival has improved dramatically as corticosteroids have become the mainstay of treatment [8]. Depending on the specific disease and severity, the length of treatment ranges from days to years to a lifetime of use. As with many medications, chronic use may result in adverse side effects. Such effects of corticosteroids have been described in multiple organ systems including the musculoskeletal system [9]. The specific effect of hypercortisolism on bone was first recognized as a feature of Cushing’s disease. Since that time, the cause-effect relationship between corticosteroid treatment and bone disease such as osteoporosis, fractures, and osteonecrosis has become more clearly established [10–12].

AB - Corticosteroids are potent anti-inflammatory drugs used to treat various adult and pediatric medical conditions. More than 30 million Americans receive corticosteroids as part of their treatment protocols for acute and chronic illnesses [1, 2]. Use of systemic corticosteroids in children has been most thoroughly studied in patients treated for acute lymphocytic leukemia (ALL), systemic lupus erythematosus (SLE), and renal transplant. In the case of ALL, the addition of corticosteroids to antileukemic protocols has been shown to improve the remission rate [3]. Current treatment protocols characterized by chemotherapy intensified by higher-dose corticosteroids are thought to be partly responsible for improved outcomes in ALL with cure rates ranging from 70 to 90 % [3–7]. In pediatric SLE, long-term survival has improved dramatically as corticosteroids have become the mainstay of treatment [8]. Depending on the specific disease and severity, the length of treatment ranges from days to years to a lifetime of use. As with many medications, chronic use may result in adverse side effects. Such effects of corticosteroids have been described in multiple organ systems including the musculoskeletal system [9]. The specific effect of hypercortisolism on bone was first recognized as a feature of Cushing’s disease. Since that time, the cause-effect relationship between corticosteroid treatment and bone disease such as osteoporosis, fractures, and osteonecrosis has become more clearly established [10–12].

UR - http://www.scopus.com/inward/record.url?scp=84955709089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955709089&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-35767-1_63

DO - 10.1007/978-3-642-35767-1_63

M3 - Chapter

SN - 9783642357671

SN - 9783642357664

SP - 479

EP - 490

BT - Osteonecrosis

PB - Springer Berlin Heidelberg

ER -